. All patients were treated with intensive insulin therapy from the onset of the disease. The inclusion criteria for the study were as follows: age between 18 and 35 years, newly diagnosed T1D and initiation of insulin therapy, as well as consent for participation in the study. Patients were assessed at the time of diagnosis (the samples collected before administration of insulin) and then at a follow -up visit in an outpatient clinic after 3 months of insulin treatment. The diagnosis of T1D was confirmed by the measurement of disease -specific autoantibodies.
Introduction Type 1 diabetes (T1D) is a chronic autoimmune disease that affects both children and adults. 1 It is extremely important to adequately treat diabetes from the onset of the disease, due to the metabolic memory phenomenon revealed in the Epidemiology of Diabetes Intervention and Complications Study. 2 The study showed that patients treated from the beginning with intensive insulin therapy derived greater benefits in the follow -up. 2 The management of diabetes includes also the assessment of lipid profile. Lipid abnormalities are common in patients with T1D and depend on metabolic control. 3 Dyslipidemia has an indisputable effect on the development of diabetic complications, including cardiovascular disease. 4 High -density lipoprotein cholesterol (HDL-C) seems to play a protective role in the development of long -term complications of T1D; however, this phenomenon is still unclear because the available data are conflicting.
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It has been shown that the initiation of insulin therapy may modify the lipid profile, including HDL-C levels. However, this trend has not been fully evaluated in patients with T1D.
6 It is necessary to investigate whether an increase in HDL-C levels depends on an insulin dose and glycation process in the course of hyperglycemia.
The aims of the study were a prospective assessment of changes in the lipid profile after initiation of insulin therapy in newly diagnosed T1D and analysis of biomarkers associated with the therapy. that may influence an increase in HDL-C levels, the impact of baseline DDI was investigated in the multiple regression model adjusted for sex, HbA 1c , and triglycerides. The differences with a probability value of less than 0.05 were considered significant. Discussion To the best of our knowledge, there has been no prospective study addressing and explaining how the initiation of insulin therapy affects HDL-C levels in newly diagnosed T1D. Our results confirm that the initiation of insulin treatment increases HDL-C levels in T1D. Moreover, this is the first study to show that an increase in HDL-C levels is dependent on an insulin dose, independently from the HbA 1c level.
Our results are in line with other studies. 6,8 Sinha et al 6 examined the effects of insulin on the lipid profile in patients with newly diagnosed T1D and in those with type 2 diabetes unsuccessfully treated with oral agents, requiring initiation of insulin therapy. The authors showed that initiation of insulin therapy improved all components of the lipid profile only in patients with T1D. The limitation of the cited study was a small number of patients (n = 9) with newly diagnosed T1D and the follow -up duration of only 6 months. In our study, we observed changes in the lipid profile over a shorter time of insulin treatment-already after 3 months.
We would like to emphasize that during our prospective observation, not only changes in the lipid profile were observed. One of our aims was to investigate whether these changes were dependent on DDI and HbA 1c . It has been shown that HDL-C protects against diabetes complications.
9
Still, the life expectancy of patients with T1D, despite the increased levels of HDL-C, is shorter than that of the general population. 10 Interestingly, Costacou and Evans 11 showed that both low and very high levels of HDL-C are associated with an increased incidence of coronary artery disease. The authors revealed a U -shaped curve for the risk of coronary artery disease in women with HDL-C concentrations below 47 mg/dl and above 80 mg/dl. Thus, it seems important to further investigate this issue. It was reported that the increase in HDL-C levels in patients with T1D may (Roche Diagnostics, Basel, Switzerland), using enzymatic colorimetric methods. Low -density lipoprotein levels were calculated by the Friedewald formula. 7 ΔHDL was defined as the difference between the value of HDL-C at onset and at follow--up. Glycated hemoglobin A 1c (HbA 1c ) levels were measured twice: at baseline and at 3 months. HbA 1c levels were assessed by a turbidimetric inhibition immunoassay using Cobas 6000. All measurements were performed in serum.
Statistical analysis The statistical analysis was performed using the STATISTICA 12.0 program (StatSoft, TIBCO Software Inc., Palo Alto, California, United States). All data were expressed as median values and interquartile ranges (IQRs) and as a number (percentage) of patients. First, the data at onset and at follow -up were compared. Then, patients were divided into 2 groups according to the median ΔHDL value (0.48 mmol/l) and baseline DDI (0.13 U/kg body weight). The MannWhitney and Wilcoxon tests were used for continuous variables, and the Fisher test or the χ 2 test for categorical variables was used to assess differences between the groups. Looking for factors for noncommercial purposes only. For commercial use, please contact the journal office at pamw@ mp.pl.
be dependent on the DDI. Guy et al 8 showed that patients with higher insulin requirement presented higher levels of HDL-C compared with patients with lower insulin requirement. These data show that the increase in HDL-C levels is closely related to the dose of insulin, similarly to our observations. However, the study by Guy et al 8 was performed on a group of youth and it was not a prospective follow -up. One of the objectives of our study was the evaluation of the relationship between the increase in HDL-C and HbA 1c levels. Guy et al 8 showed differences in the lipid profile and insulin requirement between the groups divided according to HbA 1c levels. The authors proved that patients with poor glycemic control have an atherogenic lipid pattern, including a decrease in HDL-C levels. In our study, the group with low and high ΔHDL value and low and high DDI did not differ in the level of HbA 1c at follow -up. Manjunatha et al 12 suggested that simple laboratory measurements of HbA 1c and HDL-C concentrations may be insufficient to determine cardiovascular risk in patients with T1D. They showed that despite normal HDL-C levels, its function (determined by cholesterol efflux and antioxidant capacity) is reduced in patients with long -term T1D, irrespective of glycemic control, compared with healthy controls. The authors explained this phenomenon by irreversible posttranslational modifications of the HDL-C proteins. It follows that the quality, and not the quantity, of HDL-C determines its function. In our future studies, we are planning to assess the HDL-C function in patients with newly diagnosed T1D.
The prospective analysis confirmed the association between the initiation of insulin therapy and changes in lipid profile in patients with newly diagnosed T1D. An increase in HDL-C levels was related to baseline DDI. The higher the baseline DDI, the higher the increase of HDL-C levels in adults with newly diagnosed T1D. From a clinical point of view, it is surprising that we demonstrated the relationship between insulin dose and HDL-C level in a prospective study. Due to the evidence that HDL-C may have a protective effect on diabetic complications, we should consider how to maintain normal HDL-C levels in these patients. Our findings suggest that intensive insulin therapy contributes to an increase in HDL-C levels, so it is important to investigate the mechanism of this phenomenon and its clinical implications in patients with T1D.
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